Research Article
Management of familial hypercholesterolemia in children and adolescents. Position paper of the Polish Lipid Expert Forum

Małgorzata Mysliwiec, Mieczysław Walczak, Ewa Małecka-Tendera, Anna Dobrzanska, Barbara Cybulska, Krzysztof Filipiak, Artur Mazur, Przemysława Jarosz-Chobot, Agnieszka Szadkowska, Andrzej Rynkiewicz, Alicja Chybicka, Piotr Socha, Agnieszka Brandt, Joanna Bautembach-Minkowska, Tomasz Zdrojewski, Janusz Limon, Samuel S. Gidding and Maciej Banach

Journal of Clinical Lipidology, 2014, 8(2), 173-180. DOI: 10.1016/j.jacl.2014.01.001

Abstract

Familial hypercholesterolemia (FH) affects on average 1 in 500 individuals in European countries, and it is estimated that FH in Poland may affect more than 80,000 people. However, in Poland, only about 20% of the population is estimated to have been diagnosed with FH, of which only a small number receive adequate treatment. FH results in more rapid development of atherosclerosis and is associated with a high risk of cardiovascular events. Atherosclerosis develops beginning in childhood in patients with FH and reaches advanced stages before clinical manifestations develop. Inadequate diagnostics and treatment of FH in Polish children suggests a need for raising the level of awareness and understanding of the condition in both society and among health professionals. These recommendations present the current epidemiological status, guidelines for diagnosing FH in Polish children and adolescents, and effective treatment options.

ASCI-ID: 2746-391

View Fulltext

Similar Articles


Prevalence of metabolic syndrome and insulin resistance among Egyptian adolescents 10 to 18 years of age

Journal of Clinical Lipidology, 2010, 4(3), 185-195. DOI: 10.1016/j.jacl.2010.03.007

Elevated atherogenic lipoproteins in childhood: Risk, prevention, and treatment

Journal of Clinical Lipidology, 2008, 2(3), 138-146. DOI: 10.1016/j.jacl.2008.04.006

Metabolic syndrome and dyslipidemia in youth

Journal of Clinical Lipidology, 2008, 2(3), 147-155. DOI: 10.1016/j.jacl.2008.04.005

Getting the word out: Teaching middle-school children about cardiovascular disease

Journal of Clinical Lipidology, 2008, 2(3), 179-188. DOI: 10.1016/j.jacl.2008.03.004

Lipids and lipoprotein ratios: Contribution to carotid intima media thickness in adolescents and young adults with type 2 diabetes mellitus

Journal of Clinical Lipidology, 2013, 7(5), 441-445. DOI: 10.1016/j.jacl.2013.05.002

Non-HDL-cholesterol in an adolescent diabetes population

Journal of Clinical Lipidology, 2014, 8(2), 194-198. DOI: 10.1016/j.jacl.2013.12.006

Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol?

Journal of Clinical Lipidology, 2010, 4(3), 152-155. DOI: 10.1016/j.jacl.2010.03.005

High levels of urinary F2-isoprostanes predict cardiovascular mortality in postmenopausal women

Journal of Clinical Lipidology, 2008, 2(4), 298-303. DOI: 1016/j.jacl.2008.06.004

Chronic kidney disease as a cardiovascular risk state and considerations for the use of statins

Journal of Clinical Lipidology, 2008, 2(5), 318-327. DOI: 10.1016/j.jacl.2008.06.008

Population variations in atherogenic dyslipidemia: A report from the HeartSCORE and IndiaSCORE Studies

Journal of Clinical Lipidology, 2008, 2(6), 410-417. DOI: 10.1016/j.jacl.2008.10.005

Extended-release niacin reduces LDL particle number without changing total LDL cholesterol in patients with stable CAD

Journal of Clinical Lipidology, 2009, 3(1), 45-50. DOI: 10.1016/j.jacl.2008.12.003

Postprandial lipemia as an early predictor of cardiovascular complications in childhood obesity

Journal of Clinical Lipidology, 2009, 3(2), 78-84. DOI: 10.1016/j.jacl.2009.02.006

The role of lipoprotein-associated phospholipase A2 on cardiovascular disease risk assessment and plaque rupture: a clinical review

Journal of Clinical Lipidology, 2009, 3(2), 85-93. DOI: 10.1016/j.jacl.2009.01.004

Prevention of atherosclerosis with low-density lipoprotein cholesterol lowering-lipoprotein changes and interactions: the SANDS study

Journal of Clinical Lipidology, 2009, 3(5), 322-331. DOI: 10.1016/j.jacl.2009.09.001

NLA Symposium screening and treatment of familial hypercholesterolemia: How can we do better? Opening and introductions

Journal of Clinical Lipidology, 2010, 4(5), 335-337. DOI: 10.1016/j.jacl.2010.08.016

Achieving lipid targets in adults with type 2 diabetes: The Stop Atherosclerosis in Native Diabetics Study

Journal of Clinical Lipidology, 2010, 4(5), 435-443. DOI: 10.1016/j.jacl.2010.07.007

Statin use and lipid levels in older adults: National Health and Nutrition Examination Survey, 2001 to 2006

Journal of Clinical Lipidology, 2010, 4(6), 483-490. DOI: 10.1016/j.jacl.2010.10.002

Clinical perspective: Have the results of recent clinical trials of lipid-lowering therapies influenced the way we should practice? A Latin American perspective of current issues in clinical lipidology

Journal of Clinical Lipidology, 2011, 5(3), 124-132. DOI: 10.1016/j.jacl.2011.02.006

Reliability of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B measurement

Journal of Clinical Lipidology, 2011, 5(4), 264-272. DOI: 10.1016/j.jacl.2011.05.004

Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: A review

Journal of Clinical Lipidology, 2012, 6(1), 5-18. DOI: 10.1016/j.jacl.2011.10.018

Benefits associated with achieving optimal risk factor levels for the primary prevention of cardiovascular disease in older men

Journal of Clinical Lipidology, 2012, 6(1), 58-65. DOI: 10.1016/j.jacl.2011.10.019

Fatty acids in cardiovascular health and disease: A comprehensive update

Journal of Clinical Lipidology, 2012, 6(3), 216-234. DOI: 10.1016/j.jacl.2012.04.077

Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialists' Collaboration meta-analysis for low-density lipoprotein lowering

Journal of Clinical Lipidology, 2012, 6(4), 303-309. DOI: 10.1016/j.jacl.2012.05.004

High-density lipoprotein subclasses and their relationship to cardiovascular disease

Journal of Clinical Lipidology, 2012, 6(6), 496-523. DOI: 10.1016/j.jacl.2012.03.001

Postprandial lipemia is not increased in patients with previous unprovoked venous thromboembolism

Journal of Clinical Lipidology, 2013, 7(1), 48-55. DOI: 10.1016/j.jacl.2012.06.001

Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy

Journal of Clinical Lipidology, 2014, 8(1), 18-28. DOI: 10.1016/j.jacl.2013.11.002

Education for lifestyle-based management of hyperlipidemia in children enhanced by a collaborative approach

Journal of Clinical Lipidology, 2014, 8(2), 187-193. DOI: 10.1016/j.jacl.2013.12.002

JCL Roundtable: HDL in the primary care setting

Journal of Clinical Lipidology, 2014, 8(4), 364-372. DOI: 10.1016/j.jacl.2014.05.009

A pilot study in the efficacy and safety of gemfibrozil in a pediatric population

Journal of Clinical Lipidology, 2008, 2(2), 106-111. DOI: 10.1016/j.jacl.2008.02.003

Elevated atherogenic lipoproteins in childhood: Risk, prevention, and treatment

Journal of Clinical Lipidology, 2008, 2(3), 138-146. DOI: 10.1016/j.jacl.2008.04.006

Metabolic syndrome and dyslipidemia in youth

Journal of Clinical Lipidology, 2008, 2(3), 147-155. DOI: 10.1016/j.jacl.2008.04.005

Plasma lipid profile and lipid peroxidation in beta-thalassemic children

Journal of Clinical Lipidology, 2008, 2(6), 405-409. DOI: 10.1016/j.jacl.2008.10.008

The use of lipid-lowering drugs in children

Journal of Clinical Lipidology, 2010, 4(6), 449-461. DOI: 10.1016/j.jacl.2010.10.003

A systematic review of bile acid sequestrant therapy in children with familial hypercholesterolemia

Journal of Clinical Lipidology, 2011, 5(2), 76-81. DOI: 10.1016/j.jacl.2011.01.005

The association of apolipoprotein E polymorphism and lipid levels in children with a family history of premature coronary artery disease

Journal of Clinical Lipidology, 2012, 6(1), 81-87. DOI: 10.1016/j.jacl.2011.06.017

Paradoxical Relationship Between Reactive Hyperemia Index and Age in Children with Lipid Disorders

Journal of Clinical Lipidology, 2012, 6(3), 271-272. DOI: 10.1016/j.jacl.2012.04.043

Screening and management of cardiovascular risk factors in children

Journal of Clinical Lipidology, 2013, 7(5), 390-398. DOI: 10.1016/j.jacl.2013.02.001

Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation

Journal of Clinical Lipidology, 2014, 8(2), 148-172. DOI: 10.1016/j.jacl.2014.01.002

Pediatric dyslipidemias: Prescription medication efficacy and safety

Journal of Clinical Lipidology, 2008, 2(3), 189-201. DOI: 10.1016/j.jacl.2008.04.008

Benefits of the MEDPED treatment support program for patients with familial hypercholesterolemia

Journal of Clinical Lipidology, 2009, 3(2), 94-100. DOI: 10.1016/j.jacl.2009.02.004

No evidence of impaired endothelial function or altered inflammatory state in patients with familial hypercholesterolemia treated with statins

Journal of Clinical Lipidology, 2010, 4(4), 288-292. DOI: 10.1016/j.jacl.2010.02.011

NLA Symposium screening and treatment of familial hypercholesterolemia: How can we do better? Opening and introductions

Journal of Clinical Lipidology, 2010, 4(5), 335-337. DOI: 10.1016/j.jacl.2010.08.016

Defining the challenges of FH Screening for familial hypercholesterolemia

Journal of Clinical Lipidology, 2010, 4(5), 338-341. DOI: 10.1016/j.jacl.2010.08.022

Defining the challenges of familial hypercholesterolemia screening: Introduction

Journal of Clinical Lipidology, 2010, 4(5), 342-345. DOI: 10.1016/j.jacl.2010.08.014

Familial hypercholesterolemia: Current treatment options and patient selection for low-density lipoprotein apheresis

Journal of Clinical Lipidology, 2010, 4(5), 346-349. DOI: 10.1016/j.jacl.2010.08.013

Novel therapies and new targets of treatment for familial hypercholesterolemia

Journal of Clinical Lipidology, 2010, 4(5), 350-356. DOI: 10.1016/j.jacl.2010.08.015

Patient tolerance regarding different low-density lipoprotein apheresis columns: Frequent minor side effects and high patient satisfaction

Journal of Clinical Lipidology, 2011, 5(1), 45-49. DOI: 10.1016/j.jacl.2010.11.003

Lipoprotein-associated phospholipase A2 mass and activity in children with heterozygous familial hypercholesterolemia and unaffected siblings: Effect of pravastatin

Journal of Clinical Lipidology, 2011, 5(1), 50-56. DOI: 10.1016/j.jacl.2010.11.001

A systematic review of bile acid sequestrant therapy in children with familial hypercholesterolemia

Journal of Clinical Lipidology, 2011, 5(2), 76-81. DOI: 10.1016/j.jacl.2011.01.005

Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients

Journal of Clinical Lipidology, 2011, 5(3), 133-140. DOI: 10.1016/j.jacl.2011.03.001

Antisense therapy and emerging applications for the management of dyslipidemia

Journal of Clinical Lipidology, 2011, 5(6), 441-449. DOI: 10.1016/j.jacl.2011.08.007

Management of familial hypercholesterolemia during pregnancy: Case series and discussion

Journal of Clinical Lipidology, 2012, 6(1), 88-91. DOI: 10.1016/j.jacl.2011.08.005

Apheresis in homozygous familial hypercholesterolemia: The results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia

Journal of Clinical Lipidology, 2012, 6(4), 331-339. DOI: 10.1016/j.jacl.2012.03.004

Polymorphisms in apolipoprotein E and apolipoprotein A-V do not influence the lipid response to rosuvastatin but are associated with baseline lipid levels in Chinese patients with hyperlipidemia

Journal of Clinical Lipidology, 2012, 6(6), 585-592. DOI: 10.1016/j.jacl.2012.02.005

Cholesterol efflux mediators in homozygous familial hypercholesterolemia patients on low-density lipoprotein apheresis

Journal of Clinical Lipidology, 2013, 7(2), 109-116. DOI: 10.1016/j.jacl.2012.08.001

Duplication of exon 7-12 in the low-density lipoprotein receptor gene in three Danish patients with familial hypercholesterolemia

Journal of Clinical Lipidology, 2013, 7(2), 174-177. DOI: 10.1016/j.jacl.2012.11.003

Management of familial heterozygous hypercholesterolemia: Position Paper of the Polish Lipid Expert Forum

Journal of Clinical Lipidology, 2013, 7(3), 217-221. DOI: 10.1016/j.jacl.2013.01.005

JCL Roundtable: Diagnosis of severe familial hypercholesterolemia

Journal of Clinical Lipidology, 2013, 7(6), 540-545. DOI: 10.1016/j.jacl.2013.08.003

Delayed diagnosis of familial hypercholesterolemia: A case report of two patients from Egypt

Journal of Clinical Lipidology, 2013, 7(6), 683-688. DOI: 10.1016/j.jacl.2013.08.002

Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy

Journal of Clinical Lipidology, 2014, 8(1), 18-28. DOI: 10.1016/j.jacl.2013.11.002

Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation

Journal of Clinical Lipidology, 2014, 8(2), 148-172. DOI: 10.1016/j.jacl.2014.01.002

Atherosclerosis progression in patients with autosomal dominant hypercholesterolemia in clinical practice

Journal of Clinical Lipidology, 2014, 8(4), 373-380. DOI: 10.1016/j.jacl.2014.06.002

JCL Roundtable: Drug treatment of severe forms of familial hypercholesterolemia

Journal of Clinical Lipidology, 2014, 8(1), 10-17. DOI: 10.1016/j.jacl.2013.09.004

rs1801275 Interleukin-4 receptor alpha polymorphism in familial hypercholesterolemia

Journal of Clinical Lipidology, 2014, 8(4), 418-422. DOI: 10.1016/j.jacl.2014.04.003

The SLIM study: Slo-Niacin® and Atorvastatin Treatment of Lipoproteins and Inflammatory Markers in Combined Hyperlipidemia

Journal of Clinical Lipidology, 2009, 3(3), 167-178. DOI: 10.1016/j.jacl.2009.04.052

Attainment of low-density lipoprotein cholesterol goals in coronary artery disease

Journal of Clinical Lipidology, 2010, 4(3), 173-180. DOI: 10.1016/j.jacl.2010.03.002

Point: Statins, plant sterol absorption, and increased coronary risk

Journal of Clinical Lipidology, 2008, 2(4), 304-305. DOI: 10.1016/j.jacl.2008.06.005

Misperception among physicians and patients regarding the risks and benefits of statin treatment: the potential role of direct-to-consumer advertising

Journal of Clinical Lipidology, 2008, 2(1), 51-57. DOI: 10.1016/j.jacl.2008.01.002

Pediatric dyslipidemias: Prescription medication efficacy and safety

Journal of Clinical Lipidology, 2008, 2(3), 189-201. DOI: 10.1016/j.jacl.2008.04.008

Optimal management of lipids in diabetes and metabolic syndrome

Journal of Clinical Lipidology, 2008, 2(5), 335-342. DOI: 10.1016/j.jacl.2008.08.444

Prescription omega-3 acid ethyl esters plus simvastatin 20 and 80 mg: effects in mixed dyslipidemia

Journal of Clinical Lipidology, 2009, 3(1), 33-38. DOI: 10.1016/j.jacl.2008.12.007

Atherosclerosis in a managed care plan: hypercholesterolemia treatment patterns and low-density lipoprotein cholesterol monitoring

Journal of Clinical Lipidology, 2009, 3(6), 385-392. DOI: 10.1016/j.jacl.2009.10.004

NLA Symposium screening and treatment of familial hypercholesterolemia: How can we do better? Opening and introductions

Journal of Clinical Lipidology, 2010, 4(5), 335-337. DOI: 10.1016/j.jacl.2010.08.016

Familial hypercholesterolemia: Current treatment options and patient selection for low-density lipoprotein apheresis

Journal of Clinical Lipidology, 2010, 4(5), 346-349. DOI: 10.1016/j.jacl.2010.08.013

Insights from recent meta-analysis: Role of high-density lipoprotein cholesterol in reducing cardiovascular events and rates of atherosclerotic disease progression

Journal of Clinical Lipidology, 2010, 4(5), 365-370. DOI: 10.1016/j.jacl.2010.08.008

Continuation of mortality reduction after the end of randomized therapy in clinical trials of lipid-lowering therapy

Journal of Clinical Lipidology, 2011, 5(2), 97-104. DOI: 10.1016/j.jacl.2011.01.006

Lipoprotein-associated phospholipase A2 mass and activity in children with heterozygous familial hypercholesterolemia and unaffected siblings: Effect of pravastatin

Journal of Clinical Lipidology, 2011, 5(1), 50-56. DOI: 10.1016/j.jacl.2010.11.001

Carotid intima-media thickness for the practicing lipidologist

Journal of Clinical Lipidology, 2010, 4(1), 24-35. DOI: 10.1016/j.jacl.2009.11.004

No evidence of impaired endothelial function or altered inflammatory state in patients with familial hypercholesterolemia treated with statins

Journal of Clinical Lipidology, 2010, 4(4), 288-292. DOI: 10.1016/j.jacl.2010.02.011

Statin use and lipid levels in older adults: National Health and Nutrition Examination Survey, 2001 to 2006

Journal of Clinical Lipidology, 2010, 4(6), 483-490. DOI: 10.1016/j.jacl.2010.10.002

Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia

Journal of Clinical Lipidology, 2011, 5(6), 483-492. DOI: 10.1016/j.jacl.2011.09.001

The differential effect of statins on oxidative stress and endothelial function: Atorvastatin versus pravastatin

Journal of Clinical Lipidology, 2012, 6(1), 42-49. DOI: 10.1016/j.jacl.2011.08.006

Management of familial hypercholesterolemia during pregnancy: Case series and discussion

Journal of Clinical Lipidology, 2012, 6(1), 88-91. DOI: 10.1016/j.jacl.2011.08.005

Understanding Statin Use in America and Gaps in Patient Education (USAGE): An internet-based survey of 10,138 current and former statin users

Journal of Clinical Lipidology, 2012, 6(3), 208-215. DOI: 10.1016/j.jacl.2012.03.003

Treatment options for the management of hypertriglyceridemia: Strategies based on the best-available evidence

Journal of Clinical Lipidology, 2012, 6(5), 413-426. DOI: 10.1016/j.jacl.2012.04.003

Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels

Journal of Clinical Lipidology, 2012, 6(5), 434-442. DOI: 10.1016/j.jacl.2012.04.002

Review of red yeast rice content and current Food and Drug Administration oversight

Journal of Clinical Lipidology, 2013, 7(2), 117-122. DOI: 10.1016/j.jacl.2012.09.003

Treatment pattern changes in high-risk patients newly initiated on statin monotherapy in a managed care setting

Journal of Clinical Lipidology, 2013, 7(5), 399-407. DOI: 10.1016/j.jacl.2013.06.002

An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia

Journal of Clinical Lipidology, 2013, 7(6), 561-565. DOI: 10.1016/j.jacl.2013.10.001

Design and baseline data of a pediatric study with rosuvastatin in familial hypercholesterolemia

Journal of Clinical Lipidology, 2013, 7(5), 408-413. DOI: 10.1016/j.jacl.2013.06.010

Elevation of fasting morning glucose relative to hemoglobin A1c in normoglycemic patients treated with niacin and with statins

Journal of Clinical Lipidology, 2012, 6(2), 168-173. DOI: 10.1016/j.jacl.2011.12.008

The high-dose rosuvastatin once weekly study (The HD-ROWS)

Journal of Clinical Lipidology, 2012, 6(4), 362-367. DOI: 10.1016/j.jacl.2011.11.002

An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia-Full report

Journal of Clinical Lipidology, 2014, 8(1), 29-60. DOI: 10.1016/j.jacl.2013.12.005

Muscle symptoms in statin users, associations with cytochrome P450, and membrane transporter inhibitor use: A subanalysis of the USAGE study

Journal of Clinical Lipidology, 2014, 8(1), 69-76. DOI: 10.1016/j.jacl.2013.10.006

Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease

Journal of Clinical Lipidology, 2014, 8(1), 107-116. DOI: 10.1016/j.jacl.2013.09.009

Register-based predictors of adherence among new statin users in Finland

Journal of Clinical Lipidology, 2014, 8(1), 117-125. DOI: 10.1016/j.jacl.2013.09.008

Efficacy and Safety of Multi-drug Therapy for Hypertriglceridemia

Journal of Clinical Lipidology, 2008, 2(3), 204-205. DOI: 10.1016/j.jacl.2008.04.015

Discontinuation Rate Due to Flushing Is Less than 6% Following Therapy with a Proprietary Niacin Extended-Release

Journal of Clinical Lipidology, 2008, 2(3), 210-211. DOI: 10.1016/j.jacl.2008.04.021

Adverse reactions of Achilles tendon xanthomas in three hypercholesterolemic patients after treatment intensification with niacin and bile acid sequestrants

Journal of Clinical Lipidology, 2013, 7(2), 178-181. DOI: 10.1016/j.jacl.2012.11.002

Management of familial heterozygous hypercholesterolemia: Position Paper of the Polish Lipid Expert Forum

Journal of Clinical Lipidology, 2013, 7(3), 217-221. DOI: 10.1016/j.jacl.2013.01.005

Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialists' Collaboration meta-analysis for low-density lipoprotein lowering

Journal of Clinical Lipidology, 2012, 6(4), 303-309. DOI: 10.1016/j.jacl.2012.05.004